Translational Research in Oncology: TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial
Over 5000 Patients Enrolled in 20 countries
EDMONTON, Alberta, April 21, 2021 (GLOBE NEWSWIRE) Translational Research In Oncology (TRIO) today announced completion of enrollment for Novartis phase III clinical trial of ribociclib with endocrine therapy in the adjuvant treatment of HR-positive, HER2-negative early breast cancer (EBC). The trial, referred to as NATALEE (New Adjuvant TriAl with LEE), has enrolled 5101 patients globally.
Rapid enrollment of this randomized, phase III study can be attributed to the strength of TRIO s global network consisting of 405 active investigator sites, including TRIO-US and its regional partners, and current unmet needs among the eBC patient population that includes intermediate-risk patients, as well as high-risk stage III patients.
Investegate |Translational Research in Onco Announcements | Translational Research in Onco: TRIO Completes Enrollment of Phase III NATALEE Breast Cancer Clinical Trial investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.